Search

Displaying results 4621 - 4630 of 10000 in total
  1. Drug

    Etirinotecan pegol

    go.drugbank.com/drugs/DB14951
    Investigational

    Etirinotecan pegol is under investigation in clinical trial NCT01663012 (Phase II NKTR-102 In Bevacizumab-Resistant High Grade Glioma).

    Categories: Topoisomerase 1 (TOP1) inhibitors
  2. Drug

    Pamrevlumab

    go.drugbank.com/drugs/DB14952
    Investigational

    Pamrevlumab is under investigation in clinical trial NCT00913393 (Study of FibroGen (FG)-3019 in Subjects With Type 2 Diabetes Mellitus and Kidney Disease on ACEi and/or ARB Therapy).

  3. Drug

    Firtecan pegol

    go.drugbank.com/drugs/DB14953
    Investigational

    Firtecan pegol is under investigation in clinical trial NCT01036113 (A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer).

  4. Drug

    MK-3577

    go.drugbank.com/drugs/DB14957
    Investigational

    MK-3577 is under investigation in clinical trial NCT00868790 (A Study of the Safety and Efficacy of MK-3577 in Participants With Type 2 Diabetes Mellitus (MK-3577-009)).

  5. Drug

    CTT-1057

    go.drugbank.com/drugs/DB14965
    Investigational

    CTT-1057 is under investigation in clinical trial NCT03427476 (CTT1057, a Small Molecular Inhibitor of PSMA, as a Novel Imaging Agent of Neovascularization in Renal Cell Carcinoma).

  6. Drug

    MIP-1095 I-131

    go.drugbank.com/drugs/DB14978
    Investigational

    MIP-1095 I-131 is under investigation in clinical trial NCT03030885 (Use of an Experimental Radiopharmaceutical (131I-MIP-1095) in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)).

  7. Drug

    Nomacopan

    go.drugbank.com/drugs/DB14991
    Investigational

    Nomacopan is under investigation in clinical trial NCT03427060 (Coversin in PNH in Patients With Resistance to Eculizumab Due to Complement C5 Polymorphisms).

    Categories: Recombinant Protein Inhibitor of Complement Factor 5
  8. Drug

    Pegunigalsidase alfa

    go.drugbank.com/drugs/DB14992
    ApprovedInvestigational

    Pegunigalsidase alfa (PRX-102) is a recombinant form of human α-galactosidase-A indicated for long-term enzyme replacement therapy in patients with Fabry disease, a rare genetic disorder characterized … to a different glycosylation pattern.

  9. Drug

    Sutimlimab

    go.drugbank.com/drugs/DB14996
    ApprovedInvestigational

    Cold agglutinin disease (CAD) is a type of autoimmune hemolytic anemia (AIHA) in which autoantibodies directed against red blood cell surface antigens cause hemolysis at low (3-4°C) temperatures. … [A245159,L40114] In approximately 90% of cases, patients develop immunoglobulin M (IgM) autoantibodies towards the I antigen on erythrocytes - these antibodies react optimally at 4°C and are therefore

    Synonyms: Humanized IgG4 monoclonal antibody against total complement component 1, subcomponent s
  10. Drug

    Pateclizumab

    go.drugbank.com/drugs/DB14997
    Investigational

    Pateclizumab is under investigation in clinical trial NCT01225393 (A Study to Evaluate the Efficacy and Safety of MLTA3698A in Combination With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Compared … With Adalimumab in Combination With a DMARD in Patients With Active Rheumatoid Arthritis).